◎ Sugi Atlas

Atlas / Drug / Piclidenoson

Piclidenoson

drug
On this page

Also known as ALB-7208CF-101Cf101IB-MECA

Summary

Piclidenoson (CHEMBL3989873) is a phase-3 clinical-stage small molecule targeting ADORA1, ADORA2A, and ADORA2B; indicated across 9 conditions including psoriasis and rheumatoid arthritis.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 4 (ADORA1, ADORA2A, ADORA2B…)
  • Indications: 9 conditions
  • Clinical trials: 15
  • Chemistry: 510.3 Da · C18H19IN6O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3989873
NamePiclidenoson
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID6610314
Molecular formulaC18H19IN6O4
Molecular weight510.3
InChIKeyJTZRECOPNKCRTE-MOROJQBDSA-N

SMILES: CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)I)O)O

IUPAC name: (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(4-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide

Also known as: ALB-7208, CF-101, Cf101, CF101, IB-MECA, Piclidenoson, PICLIDENOSON

Patent coverage: 311 distinct patent families (927 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ADORA1A1 receptorAgonist7.290.3%P30542
ADORA2AA2A receptorFull agonist6.30.4%P29274
ADORA2BA2B receptorFull agonist4.90.5%P29275
ADORA3A3 receptorFull agonist9.20%P0DMS8

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 4 target gene(s): ADORA1, ADORA2A, ADORA2B, ADORA3.

Top Reactome pathways

23 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction4ADORA1, ADORA2A, ADORA2B, ADORA3
Signaling by GPCR4ADORA1, ADORA2A, ADORA2B, ADORA3
Class A/1 (Rhodopsin-like receptors)4ADORA1, ADORA2A, ADORA2B, ADORA3
GPCR downstream signalling4ADORA1, ADORA2A, ADORA2B, ADORA3
Adenosine P1 receptors4ADORA1, ADORA2A, ADORA2B, ADORA3
Nucleotide-like (purinergic) receptors4ADORA1, ADORA2A, ADORA2B, ADORA3
GPCR ligand binding4ADORA1, ADORA2A, ADORA2B, ADORA3
Metabolism of proteins2ADORA2A, ADORA2B
G alpha (s) signalling events2ADORA2A, ADORA2B
G alpha (i) signalling events2ADORA1, ADORA3
Surfactant metabolism2ADORA2A, ADORA2B
Disease1ADORA2B
Signaling by NTRKs1ADORA2A
Activation of TRKA receptors1ADORA2A
NGF-independant TRKA activation1ADORA2A
Signaling by NTRK1 (TRKA)1ADORA2A
Infectious disease1ADORA2B
Signaling by Receptor Tyrosine Kinases1ADORA2A
Leishmania infection1ADORA2B
ADORA2B mediated anti-inflammatory cytokines production1ADORA2B
Anti-inflammatory response favouring Leishmania parasite infection1ADORA2B
Leishmania parasite growth and survival1ADORA2B
Parasitic Infection Pathways1ADORA2B

Dominant GO biological processes

GO termTargets
signal transduction4
G protein-coupled receptor signaling pathway4
G protein-coupled adenosine receptor signaling pathway4
inflammatory response3
negative regulation of cell population proliferation3
vasodilation3
presynaptic modulation of chemical synaptic transmission3
phagocytosis2
cell-cell signaling2
response to purine-containing compound2
excitatory postsynaptic potential2
apoptotic signaling pathway2
negative regulation of inflammatory response2
adenylate cyclase-activating G protein-coupled receptor signaling pathway2
regulation of norepinephrine secretion2

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
psoriasis3MONDO:0005083EFO:0000676
rheumatoid arthritis3MONDO:0008383EFO:0000685
dry eye syndrome3MONDO:0006733EFO:1000906
osteoarthritis, knee2MONDO:0005416EFO:0004616
intermediate uveitis2MONDO:0006806EFO:1000986
ocular hypertension2MONDO:0006875EFO:1001069
posterior uveitis2MONDO:0006918EFO:1001119
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
glaucoma2MONDO:0005041MONDO:0005041

Clinical trials

Total trials: 15.

Phase distribution

PhaseTrials
PHASE210
PHASE34
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06643260PHASE3NOT_YET_RECRUITINGA Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
NCT01235234PHASE3COMPLETEDTrial of CF101 to Treat Patients With Dry Eye Disease
NCT01265667PHASE2/PHASE3COMPLETEDTrial of CF101 to Treat Patients With Psoriasis
NCT02647762PHASE3TERMINATEDCF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
NCT03168256PHASE3COMPLETEDCF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
NCT07410455PHASE2NOT_YET_RECRUITINGAn Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome
NCT00280917PHASE2COMPLETEDOral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
NCT00349466PHASE2COMPLETEDSafety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
NCT00428974PHASE2COMPLETEDSafety and Efficacy Study of CF101 to Treat Psoriasis
NCT00556894PHASE2COMPLETEDOral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
NCT00837291PHASE2WITHDRAWNA Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee
NCT01033422PHASE2COMPLETEDSafety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
NCT01034306PHASE2COMPLETEDOral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
NCT01905124PHASE2WITHDRAWNSafety &Efficacy of CF101 to Subjects With Uveitis
NCT04333472PHASE2COMPLETEDPiclidenoson for Treatment of COVID-19

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

477 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ADENOSINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
CAFFEINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
ISTRADEFYLLINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
REGADENOSONChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
THEOPHYLLINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
BINODENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
ROLOFYLLINEChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
TONAPOFYLLINEChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
TOZADENANTChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
TRABODENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
CIFORADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
DERENOFYLLINEChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
ENPROFYLLINEChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
IMARADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
TECADENOSONChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
VIPADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
FidaxomicinChEMBL + PubChemPhase 4 (approved)ADORA1, ADORA2A, ADORA3
LinagliptinChEMBL + PubChemPhase 4 (approved)ADORA1, ADORA2A, ADORA3
PyrazinamideChEMBL + PubChemPhase 4 (approved)ADORA1, ADORA2A, ADORA3
CLOFARABINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
CLOTRIMAZOLEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
ECONAZOLEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
EPALRESTATChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
FEDRATINIBChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
MEFLOQUINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
MICONAZOLEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NEVIRAPINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NIFEDIPINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NIMESULIDEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NISOLDIPINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NITAZOXANIDEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
PENTOSTATINChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
PYRVINIUMChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
RIFAMPINChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
RIFAXIMINChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
SUNITINIBChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
TAMOXIFENChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
APADENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA3
DIACEREINChEMBLPhase 3ADORA1, ADORA2A, ADORA3
NAMODENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA3
ETRUMADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B
METRIFUDILChEMBLPhase 2ADORA1, ADORA2A, ADORA3
SONEDENOSONChEMBLPhase 2ADORA1, ADORA2A, ADORA2B
TOFIMILASTChEMBLPhase 2ADORA1, ADORA2A, ADORA3
AfatinibPubChemApprovedADORA1, ADORA2A, ADORA3
ApixabanPubChemApprovedADORA1, ADORA2A, ADORA3
BinimetinibPubChemApprovedADORA1, ADORA2A, ADORA3
BosentanPubChemApprovedADORA1, ADORA2A, ADORA3
chenodiolPubChemApprovedADORA1, ADORA2A, ADORA3
DihydroergotaminePubChemApprovedADORA1, ADORA2A, ADORA3
FulvestrantPubChemApprovedADORA1, ADORA2A, ADORA3
ImipenemPubChemApprovedADORA1, ADORA2A, ADORA3
PropoxyphenePubChemApprovedADORA1, ADORA2A, ADORA3
ALPIDEMChEMBLPhase 4 (approved)ADORA1, ADORA3
AMPHETAMINEChEMBLPhase 4 (approved)ADORA1, ADORA2A
BALSALAZIDEChEMBLPhase 4 (approved)ADORA2A, ADORA3
BITHIONOLChEMBLPhase 4 (approved)ADORA2A, ADORA3
DAUNORUBICINChEMBLPhase 4 (approved)ADORA2A, ADORA3
ENASIDENIBChEMBLPhase 4 (approved)ADORA1, ADORA3

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot